Drug is the only respiratory therapy that can be given at home every 8 weeks.
Formulary Watch
Latest News
All News
Advertisement
New HIV prevention drug not indicated for women.
Drugstore retailers pull ranitidine and Zantac products off the shelves due to cancer concerns.
Drug is first 8-week treatment approved for this type of HCV.
How the first oral GLP-1 oral treatment for type 2 diabetes is unique and how it will be priced compared to other GLP-1 medications.
FDA limits packaging for this OTC medication.
Fentanyl citrate and ephedrine sulfate are among the medications affected.
FDA is evaluating risks to patients.
Targeted therapy gives new hope to patients with an aggressive form of lung cancer.
Health groups urge Trump to appoint Acting FDA Commissioner Ned Sharpless.
Advertisement
The new drug is an add-on to levodopa/carbidopa for Parkinson’s patients experiencing “off” episodes.
Use of these meds to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in liver failure in rare cases.
Teva’s generic EpiPen Jr. helps alleviate allergy drug shortage.
DEA scrambles to add qualified marijuana growers.
FDA approved the third oncology drug in the US that targets a key genetic driver of cancer, rather than a specific tumor.
Blockbuster drug could be key to Humira’s successor.
While FDA’s drug approval time is generally improving, the agency needs to speed up generic drug application reviews, according to a new report.
While FDA recently said Novartis and AveXis did not reveal data on their $2.1 million gene thaerpy for pediatric spinal muscular atrophy until after it was approved, Novartis is defending its actions.
Drug to treat prostate cancer is expected to produce a major windfall for two pharma makers.
FDA approved yet another indication for pembrolizumab (Keytruda) to treat patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus (ESCC).
FDA is adding an important new Boxed Warning on the higher-dose version of this drug.
FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.
Patients with overactive bladder taking this OAB drug did not experience an excess risk of CV events compared with other treatments.
Asthma patients may soon treat themselves with first-ever digital maintenance inhaler.
While some are concerned that President Trump’s proposed “favored nations” policy would harm pharma makers, one analyst is not as concerned.
While some are concerned that President Trump’s proposed “favored nations” policy would harm pharma makers, one analyst is not as concerned.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
3
How PBMs are tackling behavioral health
4
Most commercial plans cover SC and IV oncology therapies at parity
5